Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Elissar Moujaes"'
Publikováno v:
Pharmacogenomics. 23:487-492
Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with gBRCA mutations. In fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d5d30128fd3c096a84415dc9c86a9a36
https://doi.org/10.2217/pgs-2022-0011
https://doi.org/10.2217/pgs-2022-0011
Publikováno v:
Pharmacogenomics. 23(8)
Talazoparib is an oral PARP inhibitor approved for locally advanced/metastatic breast cancer. There is no consensus, however, as to whether it is better used as a first-line treatment or after other therapies in patients with
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::1a6f6203c752af6d89585448c52974cf
https://pubmed.ncbi.nlm.nih.gov/35607887
https://pubmed.ncbi.nlm.nih.gov/35607887